ClinicalTrials.gg
CompletedNCT04524403Updated Jun 13, 2024Results posted

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

A Phase 2 interventional study of Miricorlilant and Miricorlilant in Antipsychotic-induced Weight Gain (AIWG), sponsored by Corcept Therapeutics. Completed at 40 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic medications.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study that will assess the safety, efficacy, and PK of miricorilant in obese patients with schizophrenia who are currently taking olanzapine, risperidone, paliperidone, or quetiapine.

Patients who meet the criteria for the Study CORT118335-877 will be randomized on Day 1 to receive 600 mg miricorilant, 900 mg miricorilant, or placebo for 26 weeks.

02

Conditions studied

  • Antipsychotic-induced Weight Gain (AIWG)

Keywords

  • Antipsychotic-induced weight gain (AIWG)
  • Obesity
  • Weight Gain
  • Mental disorders
  • Schizophrenia
  • Risperidone
  • Paliperidone
  • Quetiapine
  • Olanzapine
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 150 is above the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of schizophrenia
  • Are currently taking olanzapine, risperidone, paliperidone, or quetiapine and have gained weight from treatment while on these medications
  • Must be on a stable dose of medication for 1 month prior to Screening
  • Have a ≥30 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • Have a history of a medical condition affecting body weight (eg, poorly controlled hyper- or hypothyroidism; eating disorder such as anorexia, bulimia, or binge eating; or polycystic ovary syndrome)
  • Have poorly controlled diabetes mellitus
  • Have poorly controlled hypertension
  • Have a history of symptomatic hypotension
  • Have a history of orthostatic hypotension
  • Have a history of a seizure disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Miricorlilant 600 mg

    Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 26 weeks.

    Drug: Miricorlilant

  • Experimental
    Miricorlilant 900 mg

    Patients who meet the entry criteria will be randomized to receive 900 mg miricorilant for 26 weeks.

    Drug: Miricorlilant

  • Placebo comparator
    Placebo

    Patients who meet the entry criteria will be randomized to receive placebo for 26 weeks.

    Drug: Placebo

Interventions

  • Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing

    Also known as: CORT118335

  • Miricorilant 900 mg (6 X 150 mg) for once-daily for oral dosing

    Also known as: CORT118335

  • DrugPlacebo

    Placebo for once-daily oral dosing

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Body Weight

    Time frame: Baseline Day 1 and Week 26

Secondary outcomes

  1. Change From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo

    Time frame: Baseline Day 1 and Week 26

  2. Percentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo

    Percentage of patients achieving a ≥5% weight loss for 600 mg miricorilant versus placebo and 900 mg miricorilant versus placebo

    Time frame: Baseline Day 1 to Week 26

  3. Change From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo

    Time frame: Baseline Day 1 and Week 26

Other outcomes

  1. Number of Patients With One or More Treatment-emergent Adverse Events

    Time frame: Baseline Day 1 to Week 30

  2. Number of Patients With One or More Treatment-emergent Serious Adverse Events

    Time frame: Baseline Day 1 to Week 30

  3. Number of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation

    Time frame: Baseline Day 1 to Week 30

07

Results

Posted Jun 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Started504852
Completed333734
Not completed171118
Withdrew: Withdrawal by subject1038
Withdrew: Lost to follow-up343
Withdrew: Adverse event314
Withdrew: Non-compliant with study drug123
Withdrew: Moved010

Outcome measures

PrimaryChange From Baseline in Body Weight
Time frame:
Baseline Day 1 and Week 26
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight
kgMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Change From Baseline in Body Weight-1.41 ± 0.644-0.91 ± 0.631-1.66 ± 0.644
Statistical analysis
  • Miricorlilant 600 mg vs Placebo · Mixed Models Analysis · p = 0.7870 · Least squares mean difference: 0.24 · 95% CI -1.52 to 2.01
  • Miricorlilant 900 mg vs Placebo · Mixed Models Analysis · p = 0.4018 · Least squares mean difference: 0.75 · 95% CI -1.01 to 2.51
SecondaryChange From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo
Time frame:
Baseline Day 1 and Week 26
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo
kgMiricorilant 600 mg or 900 mgPlacebo
Change From Baseline in Body Weight for Both Dose Levels of Miricorilant Combined Versus Placebo-1.16 ± 0.454-1.65 ± 0.642
Statistical analysis
  • Miricorilant 600 mg or 900 mg vs Placebo · Mixed Models Analysis · p = 0.5228 · Least squares mean difference: 0.50 · 95% CI -1.03 to 2.02
SecondaryPercentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo

Percentage of patients achieving a ≥5% weight loss for 600 mg miricorilant versus placebo and 900 mg miricorilant versus placebo

Time frame:
Baseline Day 1 to Week 26
Reported as:
Count of participants · Participants
Percentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo
ParticipantsMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Percentage of Patients Achieving a ≥5% Weight Loss for Miricorilant Versus Placebo1278
Statistical analysis
  • Miricorlilant 600 mg vs Placebo · Regression, Logistic · p = 0.2537 · Odds ratio (or): 1.781 · 95% CI 0.661 to 4.802
  • Miricorlilant 900 mg vs Placebo · Regression, Logistic · p = 0.8740 · Odds ratio (or): 0.916 · 95% CI 0.308 to 2.722
SecondaryChange From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo
Time frame:
Baseline Day 1 and Week 26
Reported as:
Least squares mean · Ratio
Change From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo
RatioMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Change From Baseline in Waist-to-hip Ratio for Miricorilant Versus Placebo0.002 ± 0.00770.009 ± 0.00750.002 ± 0.0077
Statistical analysis
  • Miricorlilant 600 mg vs Placebo · Mixed Models Analysis · p = 0.9870 · Least squares mean difference: 0.000 · 95% CI -0.021 to 0.021
  • Miricorlilant 900 mg vs Placebo · Mixed Models Analysis · p = 0.4624 · Least squares mean difference: 0.008 · 95% CI -0.013 to 0.029
Other pre-specifiedNumber of Patients With One or More Treatment-emergent Adverse Events
Time frame:
Baseline Day 1 to Week 30
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Adverse Events
ParticipantsMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Number of Patients With One or More Treatment-emergent Adverse Events262121
Other pre-specifiedNumber of Patients With One or More Treatment-emergent Serious Adverse Events
Time frame:
Baseline Day 1 to Week 30
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Serious Adverse Events
ParticipantsMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Number of Patients With One or More Treatment-emergent Serious Adverse Events122
Other pre-specifiedNumber of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation
Time frame:
Baseline Day 1 to Week 30
Reported as:
Count of participants · Participants
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation
ParticipantsMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Number of Patients With One or More Treatment-emergent Adverse Events Leading to Study Drug Discontinuation754

Adverse events

Collected over Baseline Day 1 to Week 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Miricorlilant 600 mg0/50 (0%)1/50 (2%)8/50 (16%)
Miricorlilant 900 mg0/48 (0%)2/48 (4.2%)3/48 (6.3%)
Placebo0/52 (0%)2/52 (3.8%)4/52 (7.7%)
Most frequent serious events
Most frequent serious events
EventMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
HyponatraemiaMetabolism and nutrition disorders0/501/480/52
Pulmonary massRespiratory, thoracic and mediastinal disorders0/501/480/52
SchizophreniaPsychiatric disorders1/500/480/52
Regressive behaviorPsychiatric disorders0/500/481/52
AsthmaRespiratory, thoracic and mediastinal disorders0/500/481/52
Most frequent other events
Most frequent other events
EventMiricorlilant 600 mgMiricorlilant 900 mgPlacebo
Alanine aminotransferase increasedInvestigations4/501/480/52
HeadacheNervous system disorders4/502/481/52
Aspartate aminotransferase increasedInvestigations3/501/480/52
DizzinessNervous system disorders1/501/483/52

Baseline characteristics

All enrolled patients

Age, Continuous
Age, Continuous(years)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
Mean45.5 ± 10.8046.4 ± 10.8847.5 ± 10.2746.5 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
Female17191854
Male33293496
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
Hispanic or Latino98421
Not Hispanic or Latino404048128
Unknown or Not Reported1001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
American Indian or Alaska Native0000
Asian1113
Native Hawaiian or Other Pacific Islander0101
Black or African American28292885
White19172157
More than one race0011
Unknown or Not Reported2013
Region of Enrollment
Region of Enrollment(participants)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
United States504852150
Body weight
Body weight(kg)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
Mean115.41 ± 24.24108.02 ± 19.78118.11 ± 25.71113.98 ± 23.69
Waist-to-hip ratio
Waist-to-hip ratio(Ratio)Miricorlilant 600 mgMiricorlilant 900 mgPlaceboTotal
Mean0.991 ± 0.070.999 ± 0.060.992 ± 0.080.994 ± 0.07
08

Study locations

40 sites
  • Site #143
    Bentonville, Arkansas 72712, United States
  • Site # 249
    Little Rock, Arkansas 72211, United States
  • Site #153
    Culver City, California 90230, United States
  • Site #239
    Garden Grove, California 92845, United States
  • Site # 243
    Glendale, California 91206, United States
  • Site #134
    Lemon Grove, California 91945, United States
  • Site #163
    Oceanside, California 92056, United States
  • Site # 247
    Pico Rivera, California 90660, United States
  • Site # 229
    Rancho Cucamonga, California 91730, United States
  • Site # 237
    San Diego, California 92103, United States
  • Site # 150
    Stanford, California 94305, United States
  • Site #144
    Miami Lakes, Florida 33016, United States
  • Site #202
    Miami, Florida 33122, United States
  • Site #144
    North Miami, Florida 33161, United States
  • Site #241
    Okeechobee, Florida 34972, United States
  • Site # 240
    Chicago, Illinois 60640, United States
  • Site #140
    Chicago, Illinois 60641, United States
  • Site #140
    Lincolnwood, Illinois 60712, United States
  • Site #225
    Flowood, Mississippi 39232, United States
  • Site #224
    Saint Louis, Missouri 63125, United States
  • Site #217
    Lincoln, Nebraska 68526, United States
  • Site #151
    Las Vegas, Nevada 89102, United States
  • Site # 244
    Cedarhurst, New York 11516, United States
  • Site #216
    New York, New York 10032, United States
  • Site # 245
    New York, New York 10036, United States
  • Site #231
    Staten Island, New York 10312, United States
  • Site #231
    Staten Island, New York 10314, United States
  • Site # 248
    Charlotte, North Carolina 28211, United States
  • Site #181
    Raleigh, North Carolina 27608, United States
  • Site # 181
    Raleigh, North Carolina 27610, United States
  • Site #107
    Dayton, Ohio 45417, United States
  • Site # 230
    North Canton, Ohio 44720, United States
  • Site #166
    Philadelphia, Pennsylvania 19125, United States
  • Site #235
    Thorndale, Pennsylvania 19372, United States
  • Site #235
    West Chester, Pennsylvania 19380, United States
  • Site #223
    Austin, Texas 78754, United States
  • Site #206
    DeSoto, Texas 75115, United States
  • Site #066
    Houston, Texas 77030, United States
  • Site #165
    Richardson, Texas 75080, United States
  • Site #137
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jul 2022, 22 months.

Results were first posted in Jun 2024, 1 year 10 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 22 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2020
First posted
Aug 24, 2020
StartActual
Sep 9, 2020
Primary completionActual
Jul 29, 2022
CompletionActual
Aug 25, 2022
Results first posted
Jun 13, 2024
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04524403
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Sep 9, 2020
Primary completion
Jul 29, 2022
Completion
Aug 25, 2022
Results posted
Jun 13, 2024
Last update
Jun 13, 2024

Study contacts

Kavita Juneja, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion